H Eidtmann
Ludwig Maximilian University of Munich
16 Papers
83 Citations
H Eidtmann is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Lapatinib & Breast cancer. The author has an hindex of 8, co-authored 16 publications.
Chat about Author
Papers
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
Wolfgang Eiermann,Mahdi Rezai,Sherko Kümmel,Thorsten Kühn,M. Warm,K. Friedrichs,Andreas Schneeweiss,S Markmann,Holm Eggemann,Jörn Hilfrich,C. Jackisch,Isabell Witzel,H Eidtmann,A. Bachinger,S. Hell,J-U Blohmer +15 more
TL;DR: RS-guided chemotherapy decision-making resulted in a substantial modification of adjuvant chemotherapy usage in node-negative and node-positive ER+ EBC and was cost-saving versus current clinical practice.
144
Abstract S1-01: The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06)
Martine Piccart-Gebhart,Andrew P. Holmes,E. de Azambuja,S. Di Cosimo,Ramona F. Swaby,Michael Untch,C. Jackisch,István Láng,I. E. Smith,Frances M. Boyle,B H Xu,Carlos Barrios,R. D. Gelber,H Eidtmann,J. Baselga +14 more
TL;DR: Examination of the association between these survival endpoints and locoregional pCR (ypT0/is ypN0) was added as a secondary objective and results for EFS, OS and their association with pCR will be presented at the meeting.
28
Abstract S4-06: PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer – Prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies
S. Loibl,C Denkert,A Schneeweis,Stefan Paepke,Annika Lehmann,Mahdi Rezai,D. M. Zahm,Peter Sinn,F Khandan,H Eidtmann,Karel Dohnal,J Huober,Sherene Loi,BM Pfitzner,Peter A. Fasching,Fabrice Andre,Judith Lindner,Christos Sotiriou,Sanxing Guo,Stephan Gade,Valentina Nekljudova,Michael Untch,G. von Minckwitz +22 more
TL;DR: The frequency and prognostic associations of PIK3CA mutations in HER2+ve and triple negative (TN) primary BC by treated with neoadjuvant therapy are investigated and the results for the trastuzumab and lapatinib treated cohorts will be presented at the meeting.
15
Abstract S5-05: Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines-taxane-based chemotherapy for primary breast cancer – The phase III NATAN study (GBG 36/ABCSG XX)
G. von Minckwitz,Mahdi Rezai,H Eidtmann,Hans Tesch,J Huober,Bernd Gerber,DM Zahn,S. D. Costa,M. Gnant,J-U Blohmer,C Denkert,Claus Hanusch,C. Jackisch,Sherko Kümmel,P. A. Fasching,Andreas Schneeweiss,Stefan Paepke,Michael Untch,Valentina Nekljudova,Keyur Mehta,S. Loibl +20 more
TL;DR: This is the first post-neoadjuvant phase III study to determine overall survival, EFS with respect to the interval between surgery and randomization, bone-metastasis-free-survival, toxicity of and compliance to zoledronate, the predictive value of breast tumor response to NACT on the effect of postoperative treatment and the prognostic impact of chemotherapy induced amenorrhea in premenopausal patients.
13
Abstract S5-06: BRCA mutations, therapy response and prognosis in the neoadjuvant GeparQuinto study
PA Fasching,S. Loibl,H Eidtmann,Hans Tesch,Michael Untch,Jörn Hilfrich,Christian Schem,Mahdi Rezai,Bernd Gerber,S. D. Costa,J-U Blohmer,Tanja Fehm,J Huober,Cornelia Liedtke,V Müller,Valentina Nekljudova,Karsten Weber,Brigitte Rack,Matthias Rübner,L Wang,JN Ingle,Richard M. Weinshilboum,G. von Minckwitz,Fergus J. Couch +23 more
TL;DR: TNBC Patients with BRCA mutations showed a higher frequency of pCR than patients without BRC a mutations after treatment with epirubicin, cyclophosphamide and docetaxel (+/ bevacizumab), suggesting that BRCa mutations may influence pCR in response to treatment regimens that do not include platin chemotherapy.
10